Jim Cramer asks, why pay any attention to letters from a manager who lost money in the first quarter?
VIDEO ON MSN MONEY
The growth outlook unravels as the world's largest economies stumble. And that could be pulling stocks down at a time when investors are hoping for a Santa Claus rally.
There's so much bad news going around, it's hard to know where to start.
Here at home, the deficit-cutting supercommittee failed to deliver, raising the specter of another credit rating downgrade and the expiration of popular short-term stimulus items like payroll tax cuts and unemployment benefits.
The failure also illustrated the fact that the country is increasingly ungovernable at a time when we need swift, thoughtful policy actions.
The food company concentrates its business in developed markets that haven't seen a strong recovery.
Revenue increased just 1% in the quarter, with 80% coming from developed markets that have seen a weak recovery. Sales volume saw a 3% decline, with particularly dismal results from Australia and ongoing weak traffic trends in the U.S.
Compounding the headwinds, gross margin for the quarter worsened by 180 basis points, weighed down by commodity inflation, which outpaced pricing and productivity gains.
The country is projected to see increasing birth rates through 2016 -- and Mead Johnson Nutrition stands to gain from that rise.
The cost of turkeys has escalated this year, and some stores are deeply discounting the bird to attract shoppers.
To keep budget-minded customers from getting sticker shock, some grocery chains are deeply discounting the birds. That's created a "turkey war" between stores fighting for every last consumer dollar.
Passing on Transatlantic and buying into IBM signals a change in investment strategy.
Warren Buffett's Berkshire Hathaway (BRK.B) rarely loses a deal fight, which makes Monday's news that the legendary investor was outbid for reinsurer Transatlantic Holdings (TRH) seem like a strange sight.
However, the fact that Berkshire lost out in a hotly contested bid to a competitor a nearly a tenth of its size in Alleghany Corporation (Y) should not be so surprising, given the Omaha, Neb., holding company's move away from its traditional reinsurance and insurance base and its shift to a more diversified portfolio of industrial companies.
Capital Advisors Growth Fund manager Keith Goddard works to limit losses while maintaining potential for aggressive growth.
All too often, large growth funds have followed a volatile pattern. During bull markets, the growth funds soared as investors bid up prices of fast-moving technology and consumer stocks. Then the rally ended and growth stocks crashed hard as overvalued shares sank.
Because of the regular collapses, the large growth category has often trailed large value. From 1928 through 2010, large growth stocks returned 8.8% annually, compared to a figure of 11.1% for large value, according to Ibbotson Associates. In recent years, growth stocks have sunk twice -- after the Internet bubble burst in 2000 and when the financial crisis unfolded in 2008. Hurt by the downturns, large growth funds trailed the S&P 500 ($INX) during the past decade, while large value funds outdid the benchmark.
The stock has now dropped below its $20-per-share IPO price.
Updated: 4:35 p.m. ET
Shares of Groupon (GRPN), which soared 40% two weeks ago during the daily deal site's IPO, continued to crater on Wednesday.
The stock fell 15.5% to $16.96. The session low was $16.84. Volume continued to be elevated with more than 5 million shares changing hands by midday. Wednesday's decline follows a 15% drop on Tuesday.
The health care products maker is spending $325 million on a private company to bolster its presence in the gastrointestinal diseases therapy space.
By: Zacks Equity Research
Leading health care products maker Covidien (COV) has cut a deal to buy the outstanding shares of Barrx Medical for $325 million, hoping the move will boost its presence in the gastrointestinal diseases therapy space.
Barrx Medical makes ablation catheters and other devices for treating gastrointestinal diseases and Barrett’s esophagus syndrome, a pre-cancerous condition of the lining of the esophagus.
The farm machinery maker saw quarterly sales rise 20% from a year earlier to $8.6 billion.
Deere & Co. (DE) outperformed in its fourth quarter, riding a wave of strong demand for farm machinery and increased sales of construction equipment.
The equipment maker delivered earnings of $1.62 per share in the quarter ended Oct. 31, comfortably exceeding the Zacks Consensus Estimate of $1.44. Results were 51% ahead of the $1.07 earned in the year-ago quarter.
Early indicators show that Black Friday could be a hit for retailers. Will the rest of the holiday season follow suit?
Retailers are hoping that their enthusiasm signals a strong performance for Black Friday, the traditional start of the holiday season. The National Retail Federation recently said that more Americans say they plan to shop for Black Friday bargains than last year. Consumer confidence rose in November to its highest level in November to its highest level in five months.
The two drug companies end a rocky 10-year partnership. What's next for Amylin?
Amylin (AMLN) made news recently when it was announced that Eli Lilly (LLY) had broken a deal between the companies for two Type 2 diabetes treatments, Byetta and Bydureon.
Amylin has also settled a marketing lawsuit it filed against Lilly this year alleging anti-competitive activity after Lilly entered into a marketing deal with Boehringer Ingelheim to sell a competing diabetes drug.
The divorce ends a rocky 10-year partnership between the two companies.
We expect the automaker to rein in development costs after completing work on the Model S and a new plant.
But Tesla's costs also increased substantially year over year, primarily due to higher research and development expenses.
While the market's pullback to key support is a caution sign for now, it’s also likely to result in a rally next week -- one critical to the market’s intermediate-term future.
By Tom Aspray, MoneyShow.com
The heavy selling Monday and additional losses on Tuesday have taken the major averages to the next key areas of support. Additional selling in the S&P futures early Wednesday has taken them below the 50% Fibonacci support levels.
For those not familiar with Fibonacci analysis, if prices break below the 50% support, it implies that prices will then drop to the 61.8% support. A daily close below that level will give confirmation that the trend has changed from up to down. Of course, in declining markets, we watch to see if the 38.2% retracement resistance is overcome, and if it is, we then look at the 50% and 61.8% retracement resistance levels.
The aircraft maker's recent 200-plane order from American Airlines' parent now looks a lot shakier.
Although the congressional supercommittee's colossal failure this week points to the near certainty of massive defense cuts, few analysts are shedding tears for Boeing (BA) right now. One reason is the nearly $40 billion in orders the aircraft maker has booked this month alone.
JPMorgan has brought in the most investment banking revenue for at least seven consecutive quarters, but it may lose its crown as 2011 comes to a close.
JPMorgan's investment banking division has brought in more revenues than its counterparts at other banks in every quarter going back to at least the first quarter of last year, according to the Barclays Capital report, which cites Dealogic data.
MORE ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
Stocks are facing some serious resistance as the bears tear into the market's respite.
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
[BRIEFING.COM] The stock market finished the Wednesday session on a modestly lower note, but it is worth mentioning today's retreat took place after six consecutive gains. The Dow Jones Industrial Average (-0.1%) and S&P 500 (-0.2%) settled not far below their flat lines, while the Nasdaq Composite (-0.8%) lagged throughout the session.
Equity indices started the day in the red, with the Nasdaq showing early weakness as large cap tech names and biotechnology weighed. The technology ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|